EI
ASMB icon

EAM Investors’s Assembly Biosciences ASMB Stock Holding History

EAM Investors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,523
Closed -$1M – 285
2025
Q4 		$1M Buy
29,523
+451
+2% +$14.5K 0.11% 209
2025
Q3 		$744K Buy
+29,072
New +$638K 0.09% 222
2018
Q2 		– Sell
-2,695
Closed -$1.59M – 292
2018
Q1 		$1.59M Sell
2,695
-434
-14% -$269K 0.26% 157
2017
Q4 		$1.7M Buy
3,129
+1,999
+177% +$905K 0.3% 157
2017
Q3 		$474K Sell
1,130
-342
-23% -$105K 0.06% 283
2017
Q2 		$365K Sell
1,472
-629
-30% -$177K 0.06% 290
2017
Q1 		$643K Buy
+2,101
New +$515K 0.1% 262

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

EAM Investors's ASMB Position: Q1 2026 in Review

EAM Investors sold out of Assembly Biosciences (ASMB) in Q1 2026, closing a stake of 29,523 shares — an estimated $1M sold.

EAM Investors first reported a position in ASMB in Q1 2017 and held it in 7 quarters. The position peaked at $1.7M in Q4 2017. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • EAM Investors reported no remaining Assembly Biosciences position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 29,523 Assembly Biosciences shares in Q1 2026, an estimated $1M.
  • EAM Investors first reported a position in Assembly Biosciences in Q1 2017 and held it in 7 quarters.
  • EAM Investors's Assembly Biosciences position peaked at $1.7M in Q4 2017.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.